Chemotherapy + Atezolizumab for Colon Cancer
Trial Summary
What is the purpose of this trial?
This trial is testing whether adding atezolizumab to standard chemotherapy works better than chemotherapy alone for patients with stage III colon cancer who have a specific genetic defect. The chemotherapy drugs aim to kill cancer cells, while atezolizumab helps the immune system attack the cancer. Researchers hope this combination will improve survival rates and quality of life for these patients.
Will I have to stop taking my current medications?
The trial protocol does not specify if you need to stop taking your current medications. However, you cannot be on systemic daily treatment with corticosteroids or other immunosuppressive medications within 7 days of registration.
What data supports the effectiveness of the drug combination of Atezolizumab, Tecentriq, Leucovorin Calcium, Fluorouracil, and Oxaliplatin for colon cancer?
Is the combination of chemotherapy drugs and Atezolizumab safe for colon cancer treatment?
The combination of chemotherapy drugs like oxaliplatin, leucovorin, and 5-fluorouracil (FOLFOX) has been studied for colon cancer, showing some side effects such as nerve damage, low white blood cell counts, and mouth sores. These side effects are common but manageable, and the treatment is generally considered safe for use in humans.678910
How is the drug combination of chemotherapy and Atezolizumab unique for colon cancer treatment?
This treatment combines standard chemotherapy drugs (Leucovorin Calcium, Fluorouracil, Oxaliplatin) with Atezolizumab, an immunotherapy drug that helps the immune system attack cancer cells. This combination is unique because it adds an immune-boosting component to the traditional chemotherapy regimen, potentially enhancing the overall effectiveness against colon cancer.1011121314
Research Team
Frank A Sinicrope
Principal Investigator
Alliance for Clinical Trials in Oncology
Eligibility Criteria
This trial is for patients with stage III colon cancer and deficient DNA mismatch repair. Eligible participants must not have autoimmune diseases, active hepatitis B or C, severe allergies to certain antibodies or components in atezolizumab, nor require daily steroids or immunosuppressants. They should have proper liver and kidney function, no history of severe allergic reactions to specific proteins, and no prior treatments except possibly one cycle of mFOLFOX6.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Patients receive combination chemotherapy with or without atezolizumab. Chemotherapy includes oxaliplatin, leucovorin calcium, and fluorouracil. Atezolizumab is administered in Arm I.
Follow-up
Participants are monitored for disease recurrence and survival. Imaging and blood sample collection are conducted.
Long-term follow-up
Participants are followed up for survival every 6 months for up to 8 years.
Treatment Details
Interventions
- Atezolizumab
- Leucovorin Calcium, Fluorouracil, Oxaliplatin
Find a Clinic Near You
Who Is Running the Clinical Trial?
National Cancer Institute (NCI)
Lead Sponsor